Ping Yuan

Dr. Ping Yuan

Peking university health science center, Beijing, China
orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 August 2023 in Chinese Medical Journal
Verified
Journal Article
Open access
DLDong Li
Dong Li
YCYinchu Cheng
Yinchu Cheng
Ping YuanPing Yuan
Ping Yuan
ZWZiyang Wu
Ziyang Wu
JLJiabang Liu
Jiabang Liu
ZGZhen-peng Guan
Zhen-peng Guan
Background: Clinical trial evidence is limited to identify better topical non-steroidal anti-inflammatory drugs (NSAIDs) for treating knee osteoarthritis (OA). We aimed to compare the clinical efficacy and safety of flurbiprofen cataplasms (FPC) with loxoprofen sodium cataplasms (LSC) in treating patients with knee OA. Methods: This is an open-label, non-inferiority randomized controlled trial conducted at Peking University Shougang Hospital. Overall, 250 patients with knee OA admitted from October 2021 to April 2022 were randomly assigned to FPC and LSC treatment groups in a 1:1 ratio. Both medications were administered to patients for 28 days. The primary outcome was the change of pain measured by visual analog scale (VAS) score from baseline to day 28 (range, 0–10 points; higher score indicates worse pain; non-inferiority margin: 1 point; superiority margin: 0 point). There were four secondary outcomes, including the extent of pain relief, the change trends of VAS scores, joint function scores measured by the Western Ontario and McMaster University Osteoarthritis Index (WOMAC), and adverse events. Results: Among 250 randomized patients (One patient without complete baseline record in the flurbiprofen cataplasms was excluded; age, 62.8 ± 10.5 years; 61.4% [153/249] women), 234 (93.6%) finally completed the trial. In the intention-to-treat analysis, the decline of the VAS score for the 24-h most intense pain in the FPC group was non-inferior, and also superior to that in the LSC group (differences and 95% confidence interval, 0.414 (0.147–0.681); P <0.001 for non-inferiority; P = 0.001 for superiority). Similar results were observed of the VAS scores for the current pain and pain during exercise. WOMAC scores were also lower in the FPC group at week 4 (12.50 [8.00–22.50] vs . 16.00 [11.00–27.00], P = 0.010), mainly driven by the dimension of daily activity difficulty. In addition, the FPC group experienced a significantly lower incidence of adverse events (5.6% [7/124] vs . 33.6% [42/125], P <0.001), including irritation, rash and pain of the skin, and sticky hair uncovering pain. Conclusions: This study suggested that FPC is superior to LSC for treating patients with knee OA in pain relief, joint function improvement, and safety profile.

17 September 2025 in Chinese Medical Journal
Verified
Journal Article
Open access
XWXianjie Wei
Xianjie Wei
HHHesuyuan Huang
Hesuyuan Huang
Ping YuanPing Yuan
Ping Yuan
PXPeisen Xie
Peisen Xie
KZKeshi Zhang
Keshi Zhang
ZGZhen-peng Guan
Zhen-peng Guan
Background: Osteoarthritis (OA) is a prevalent joint disorder that significantly impairs quality of life among elderly individuals because of chronic pain and physical disability. As the global burden of OA continues to rise, novel therapeutic strategies are urgently needed. Kaempferide (KA), a flavonoid derived from traditional Chinese herbal medicine, is known for its anti-inflammatory properties. However, the effect of KA on the progression of OA has not been well investigated. This study aimed to explore the therapeutic potential of KA in an OA model and investigate the underlying mechanisms via transcriptomic sequencing. Methods: An in vitro OA model was established using SW1353 cells treated with interleukin-1 beta (IL-1β) and different concentrations of KA (30, 60, or 90 μmol/L) for 24 h. The anti-inflammatory effects of KA were assessed using quantitative real-time polymerase chain reaction (qRT-PCR), enzyme-linked immunosorbent assay (ELISA), and Western blotting. In vivo , a papain-induced OA rat model was used to evaluate the therapeutic effects of KA through histological and behavioral analyses. Transcriptomic sequencing was performed to explore the differentially expressed genes (DEGs) and related signaling pathways. Statistical analysis was conducted using one-way analysis of variance. Results: KA significantly increased cell viability in the OA chondrocyte model and downregulated the expression of inflammatory cytokines and cartilage degradation markers, with the greatest reduction observed at 90 μmol/L. In vivo , KA treatment mitigated cartilage degradation and improved gait behavior in OA rats. Transcriptomic analysis revealed substantial modulation of DEGs, implicating the hypoxia-inducible factor-1 (HIF-1) signaling pathway as a key mechanism. Further blocking and rescue experiments revealed that KA regulated key molecules within the HIF-1 pathway, specifically interferon-gamma (IFN-γ) and hypoxia-inducible factor 1-alpha (HIF-1α), confirming their critical roles in mediating the therapeutic effects of KA. Conclusion: KA inhibited the progression of OA by targeting the HIF-1 signaling pathway, reducing inflammation, and cartilage degradation.

1 November 2023 in Vascular Health and Risk Management
Verified
Journal Article
Open access
PDF file
FWFang Wen
Fang Wen
SJShantong Jiang
Shantong Jiang
Ping YuanPing Yuan
Ping Yuan
JLJinbo Liu
Jinbo Liu
XBXiu Bai
Xiu Bai
Hongyu WangHongyu Wang
Hongyu Wang
Cardiovascular disease(CVD) has become a major disease burden affecting people’s health in China. Blood vessels are very important for human health and are the “sentinel” for the development of many cardiovascular and cerebrovascular diseases. The key to effectively preventing fatal, disabling heart, brain and peripheral vascular events lies in controlling traditional and non-traditional risk factors for vascular health from the source, and early assessment and intervention of early vascular lesions. Since 2004, China government promoted the early detection technology of vascular lesions and vascular medicine, and proposed the Beijing Vascular Health Stratification (BVHS) to provide suggestions for the examination, evaluation and management of risk factors, and to provide new ideas for lifelong maintenance of vascular health. This review mainly introduces the establishment and development of the clinical discipline of “vascular medicine” in the past 20 years in China, introduces the indicators for detecting vascular function and structure and the predictive value of vascular events, and carries out intelligent and digital management of vascular health throughout the life cycle of individualized prevention, treatment and rehabilitation for people with different parts or degrees of lesions, effectively reducing the occurrence and development of cardiovascular and cerebrovascular diseases, and the prospect of new technology in maintaining vascular health.

23 April 2020 in medRxiv
Verified
Preprint
Open access
PDF file
CTChong Tang
Chong Tang
KZKeshi Zhang
Keshi Zhang
WWWenlong Wang
Wenlong Wang
ZPZheng Pei
Zheng Pei
ZLZheng Liu
Zheng Liu
JGJin Gu
Jin Gu
Coronavirus disease 2019 (COVID-19) is a global pandemic and has been widely reported; however, a comprehensive systemic review and meta-analysis has not been conducted. We systematically investigated the clinical characteristics of COVID-19 in mainland China to guide diagnosis and treatment. We searched the PubMed, Embase, Scopus, Web of Science, Cochrane Library, bioRxiv, medRxiv, and SSRN databases for studies related to COVID-19 published or preprinted in English or Chinese from January 1 to March 15, 2020. Clinical studies on COVID-19 performed in mainland China were included. We collected primary outcomes including signs and symptoms, chest CT imaging, laboratory tests, and treatments. Study selection, data extraction, and risk of bias assessment were performed by two independent reviewers. Qualitative and quantitative synthesis was conducted, and random-effects models were applied to pooled estimates. This study is registered with PROSPERO (number CRD42020171606). Of the 3624 records identified, 147 studies (20,662 patients) were analyzed. The mean age of patients with COVID-19 was 49.40 years, 53.45% were male, and 38.52% had at least one comorbidity. Fever and cough were the most common symptoms, followed by fatigue, expectoration, and shortness of breath. Most patients with COVID-19 had abnormal chest CT findings with ground glass opacity (70.70%) or consolidation (29.91%). Laboratory findings shown lymphopenia, increased lactate dehydrogenase, increased infection-related indicators, and fibrinolytic hyperactivity. Antiviral therapy, antibiotic therapy, and corticosteroids were administered to 89.75%, 79.13%, and 35.64% of patients, respectively. Most clinical characteristics of COVID-19 are non-specific. Patients with suspected should be evaluated by virological assays and clinically treated.

1 January 2022 in INQUIRY: The Journal of Health Care Organization, Provision, and Financing
Verified
Journal Article
Open access
HWHongyu Wang
Hongyu Wang
Ping YuanPing Yuan
Ping Yuan
CTChong Tang
Chong Tang
ZGZhenpeng Guan
Zhenpeng Guan
PXPingchao Xiang
Pingchao Xiang
JGJin Gu
Jin Gu
By September 20, 2021, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been pandemic in 237 countries and regions, resulting in 228,506,698 confirmed cases and 4,692,361 deaths. At the same time, a total of 1123 cases of COVID-19 had been confirmed in Beijing, China. Peking University Shougang Hospital has 4 community hospitals with 174 staff members, covering 230,000 residents in Shijingshan district, Beijing. The community hospitals were the basic units of China’s healthcare system for public health services, as the main battlefield for screening and controlling of COVID-19. We reported our experience about the prevention of SARS-CoV-2. We suggest that community hospitals should change their process for admitting patients. While the screening of suspected cases of COVID-19 is vital, patients with suspected infections should be isolated immediately.

28 May 2022 in SSRN Electronic Journal
Verified
Preprint
Open access
PDF file
Ping YuanPing Yuan
Ping Yuan
KZKeshi Zhang
Keshi Zhang
CTChong Tang
Chong Tang
ZXZhe Xue
Zhe Xue
TLTengqi Li
Tengqi Li
ZGZhenpeng Guan
Zhenpeng Guan
Background: This study examined the distribution of symptomatic knee osteoarthritis (SKOA) according to sociodemographic characteristics and its association with the utilization of healthcare service and catastrophic health expenditure. It compared the effect of 14 common chronic diseases on healthcare usage and spending. Methods: We used the data from three waves (2011, 2015, 2018) of the China Health and Retirement Longitudinal Study (CHARLS). Participants aged 45 and over in 2011 were included in this study. We used catastrophic health expenditure as the index for health spending. Findings: The baseline survey of CHARLS comprised 17,708 participants, and 9,660 were eligible for inclusion. In 2018, the participants’ median age was 64 years (IQR, 58–70); 48·1% were men; and the overall SKOA prevalence was 30·3% (weighted prevalence, 28·5%). SKOA prevalence increased with age and was higher in women, higher socio-economic groups, and rural areas. SKOA was most common in western China. It was associated with increased outpatient visits (incidence rate ratio, 1·62; 95% confidence interval, 1·51–1·74) and inpatient hospital stay (1·75, 1·62–1·90), and a significantly increased probability of catastrophic health expenditure (odds ratio,,1·64; 95% CI, 1·49–1·81), with its effect persisting even among higher socio-economic groups. Interpretation: Concerted efforts are needed to develop early prevention measures and screening methods for SKOA, especially for middle-aged people. Funding Information: None. Declaration of Interests: We declare no competing interests. Ethics Approval Statement: The CHARLS study was approved by the Biomedical Ethics Review Committee of Peking University (approval number: IRB00001052-11015), and all of the participants signed informed consent forms.